287 related articles for article (PubMed ID: 445418)
1. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.
Inaba M; Kobayashi H; Sakurai Y; Johnson RK
Cancer Res; 1979 Jun; 39(6 Pt 1):2200-3. PubMed ID: 445418
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
3. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
5. Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.
Inaba M; Johnson RK
Cancer Res; 1977 Dec; 37(12):4629-34. PubMed ID: 922743
[TBL] [Abstract][Full Text] [Related]
6. Intracellular adriamycin levels and cytotoxicity in adriamycin-sensitive and adriamycin-resistant P388 mouse leukemia cells.
Ganapathi R; Reiter W; Krishan A
J Natl Cancer Inst; 1982 Jun; 68(6):1027-32. PubMed ID: 6953267
[TBL] [Abstract][Full Text] [Related]
7. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
[TBL] [Abstract][Full Text] [Related]
9. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
10. Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy.
Yanovich S; Taub RN
Cancer Res; 1983 Sep; 43(9):4167-71. PubMed ID: 6871858
[TBL] [Abstract][Full Text] [Related]
11. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
Ramu A; Fuks Z; Gatt S; Glaubiger D
Cancer Res; 1984 Jan; 44(1):144-8. PubMed ID: 6690032
[TBL] [Abstract][Full Text] [Related]
12. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
13. Exploring multidrug resistance using rhodamine 123.
Kessel D
Cancer Commun; 1989; 1(3):145-9. PubMed ID: 2639727
[TBL] [Abstract][Full Text] [Related]
14. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
15. Elevated pentose cycle and glucuronyltransferase in daunorubicin-resistant P388 cells.
Gessner T; Vaughan LA; Beehler BC; Bartels CJ; Baker RM
Cancer Res; 1990 Jul; 50(13):3921-7. PubMed ID: 2112982
[TBL] [Abstract][Full Text] [Related]
16. Influence of microenvironmental pH on adriamycin resistance.
Alabaster O; Woods T; Ortiz-Sanchez V; Jahangeer S
Cancer Res; 1989 Oct; 49(20):5638-43. PubMed ID: 2790781
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
18. Comparative uptake of adriamycin and daunorubicin in sensitive and resistant friend leukemia cells measured by flow cytometry.
Tapiero H; Fourcade A; Vaigot P; Farhi JJ
Cytometry; 1982 Mar; 2(5):298-302. PubMed ID: 6951693
[TBL] [Abstract][Full Text] [Related]
19. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy.
Gervasoni JE; Fields SZ; Krishna S; Baker MA; Rosado M; Thuraisamy K; Hindenburg AA; Taub RN
Cancer Res; 1991 Sep; 51(18):4955-63. PubMed ID: 1680024
[TBL] [Abstract][Full Text] [Related]
20. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
Inaba M; Nagashima K
Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
